PDCD1 and myocarditis: Anti-PD-1 antibody therapy leads to more cases of cardiac adverse effects than anti-CTLA-4 therapy [49,50] and several reports and meta-analyses studies have reported increased cases and worse prognosis of myocarditis patients treated with ICIs in combination compared to monotherapies [7,11,49,50].